Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
Vaxxinity, Inc. (VAXX)
Company Research
Source: GlobeNewswire
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its anti-tau program in Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Portugal. Presentation details are as follows: Oral PresentationTitle: Evidence of Target Engagement in a Phase 1 Clinical Trial of UB-312 in Parkinson’s DiseasePresenter: Jean-Cosme Dodart, Ph.D., SVP of Research at VaxxinityLocation: Auditorium VIIIDate & Time: March 6, 2024 at 6:00 PM WET Poster PresentationTitle: A Randomized, Double Blind, Placebo-Controlled Study with UB-312, an Anti-Alpha-Synuclein Peptide Vaccine in Parkinson’s Disease PatientsPoster Number: P1049 / #720Authors: Pepij
Show less
Read more
Impact Snapshot
Event Time:
VAXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VAXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VAXX alerts
High impacting Vaxxinity, Inc. news events
Weekly update
A roundup of the hottest topics
VAXX
News
- Vaxxinity Issues Shareholder Letter [Yahoo! Finance]Yahoo! Finance
- Vaxxinity Issues Shareholder LetterGlobeNewswire
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock [Yahoo! Finance]Yahoo! Finance
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockGlobeNewswire
- Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
VAXX
Earnings
- 3/27/24 - Beat
VAXX
Sec Filings
- 5/3/24 - Form EFFECT
- 4/30/24 - Form S-8
- 4/30/24 - Form S-8
- VAXX's page on the SEC website